This clinical trial for patients with TTR amyloidosis (FAP) is sponsored by Alnylam Pharmaceuticals, Inc. Alnylam is a biopharmaceutical company leading the study of a new class of investigational medicines for conditions like TTR amyloidosis (FAP). These investigational medicines have genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.